Emerging drugs in chronic myelogenous leukaemia (Q36634266)

15 August 2017

1 reference

title

Emerging drugs in chronic myelogenous leukaemia (English)

1 reference

15 August 2017

1 reference

Monica Bocchia

1 reference

15 August 2017

Francesco Forconi

series ordinal

1 reference

15 August 2017

Francesco Lauria

series ordinal

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

651-664

1 reference

The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Interferon therapy in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

How long will chronic myeloid leukemia patients treated with imatinib mesylate live?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Clinical resistance to imatinib: mechanisms and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Overcoming drug resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Molecular mechanisms of resistance of leukemia to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Punish the parent not the progeny.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Can we afford to let sleeping dogs lie?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Protease inhibitors potentiate chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Critical role for Gab2 in transformation by BCR/ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.651

10.1517/14728214.11.4.651

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference